Jürgen Alt

3.7k total citations
14 papers, 228 citations indexed

About

Jürgen Alt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Sociology and Political Science. According to data from OpenAlex, Jürgen Alt has authored 14 papers receiving a total of 228 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 3 papers in Sociology and Political Science. Recurrent topics in Jürgen Alt's work include Lung Cancer Treatments and Mutations (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cancer survivorship and care (3 papers). Jürgen Alt is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cancer survivorship and care (3 papers). Jürgen Alt collaborates with scholars based in Germany, Austria and United Kingdom. Jürgen Alt's co-authors include Daniel C. Christoph, Petros Christopoulos, Martin Faehling, Dirk Schürmann, Marcel Berger, Ralf Schmidmaier, W. Brückl, Christian Hoffmann, Philipp Schütt and Anke Schlenska‐Lange and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Jürgen Alt

13 papers receiving 223 citations

Peers

Countries citing papers authored by Jürgen Alt

Since Specialization

Citations

This map shows the geographic impact of Jürgen Alt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jürgen Alt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jürgen Alt more than expected).

Fields of papers citing papers by Jürgen Alt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jürgen Alt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jürgen Alt. The network helps show where Jürgen Alt may publish in the future.

Co-authorship network of co-authors of Jürgen Alt

This figure shows the co-authorship network connecting the top 25 collaborators of Jürgen Alt. A scholar is included among the top collaborators of Jürgen Alt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jürgen Alt. Jürgen Alt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Assessment of decision-making with locally run and web-based large language models versus human board recommendations in otorhinolaryngology, head and neck surgery 2025 ·European Archives of Oto-Rhino-Laryngology ·(unknown), Benjamin Philipp Ernst, Andrew Blaikie, (unknown), Tom Kelsey, (unknown), Maximilian Fleischmann, Florian Jungmann, Jürgen Alt, Christian Brandts, Peer W. Kämmerer, Sebastian Foersch, Sebastian Kühn, Jonas Eckrich	4
2	Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab – the randomized phase 2 FOCUS trial 2024 ·Frontiers in Oncology ·Anna Brandt, Christoph Schultheiß, Konrad Klinghammer, Philippe Schafhausen, Chia‐Jung Busch, (unknown), Axel Hinke, Mareike Tometten, Andreas Dietz, Urs Müller‐Richter, D Hahn, Jürgen Alt, Alexander Stein, Mascha Binder	7
3	“That was a tip from my physician”—Gender‐specific pathways of patients and relatives to outpatient psychosocial cancer counselling centres—A qualitative study 2022 ·Psycho-Oncology ·(unknown), (unknown), Marlene Hechtner, Kathy Taylor, Jennifer M. Lang, Jürgen Alt, (unknown), Susanne Singer	7
4	Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis 2022 ·Therapeutic Advances in Medical Oncology ·Jan Stratmann, (unknown), Akin Atmaca, (unknown), Nikolaj Frost, Jürgen Alt, Cornelius F. Waller, Niels Reinmuth, Gernot Rohde, Felix Carl Saalfeld, (unknown), (unknown), (unknown), (unknown), Martin Sebastian	16
5	What is the best time for psychosocial counselling from the perspective of cancer patients and their relatives? A multi‐centre qualitative study 2021 ·Counselling and Psychotherapy Research ·Susanne Singer, (unknown), (unknown), Kathy Taylor, (unknown), (unknown), Jürgen Alt, Georg Heß, Marlene Hechtner, (unknown)	6
6	Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program 2021 ·Therapeutic Advances in Medical Oncology ·Nikolaj Frost, Petros Christopoulos, Diego Kauffmann‐Guerrero, Jan Stratmann, Richard Riedel, (unknown), Jürgen Alt, S Gütz, Daniel C. Christoph, Eckart Laack, Martin Faehling, Richard Fischer, Klaus Fenchel, Sebastian P. Haen, Lukas C. Heukamp, Christian Schulz, Frank Griesinger	33
7	PD1-1-1 Phase Ib study of BI 836880 (VEGF/Ang2 nanobody®) plus ezabenlimab (BI 754091, anti-PD-1 antibody) in patients with solid tumors 2021 ·Annals of Oncology ·Nicolas Girard, Martin Wermke, Fabrice Barlési, Dong‐Wan Kim, François Ghiringhelli, Jaafar Bennouna, Thierry Lesimple, Enriqueta Felip, David Berz, Jong-Seok Lee, (unknown), Victoria Chen, (unknown), Jürgen Alt, Björn Hackanson	2
8	Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP) 2020 ·Lung Cancer ·Martin Faehling, Christian Schumann, Petros Christopoulos, Petra Hoffknecht, Jürgen Alt, (unknown), Stephan Eisenmann, Anke Schlenska‐Lange, Philipp Schütt, Felix Steger, W. Brückl, Daniel C. Christoph	50
9	Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP 2020 ·SHILAP Revista de lepidopterología ·Martin Faehling, Christian Schumann, Petros Christopoulos, Petra Hoffknecht, Jürgen Alt, (unknown), Stephan Eisenmann, Anke Schlenska‐Lange, Philipp Schütt, Felix Steger, W. Brückl, Daniel C. Christoph	3
10	Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors 2020 ·Journal of Oncology Pharmacy Practice ·(unknown), Jürgen Alt, (unknown), Geothy Chakupurakal, Jan Stratmann, Irene Krämer	0
11	Was Männer davon abhält, ambulante Krebsberatungsstellen aufzusuchen. Eine qualitative Studie 2020 ·Der Onkologe ·(unknown), (unknown), Jürgen Alt, Georg Heß, (unknown), (unknown), (unknown), (unknown), Marlene Hechtner, Susanne Singer	17
12	Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer 2019 ·Oncology Research and Treatment ·(unknown), Nadežda Basara, Wolfgang Schütte, E. Späth‐Schwalbe, Jürgen Alt, Steffen Thiel, Martin Kimmich, Jürgen R. Fischer, (unknown), Frank Griesinger, Daniel C. Christoph	7
13	Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer 2018 ·Journal of Cancer Research and Clinical Oncology ·Jan Stratmann, Sebastian Michels, (unknown), Daniel C. Christoph, (unknown), Werner Spengler, Helge Bischoff, (unknown), Jürgen Alt, Annette Müller, Eckart Laack, Martin Kimmich, Frank Griesinger, Martin Sebastian	8
14	Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study 2012 ·Journal of Clinical Oncology ·Marcus Hentrich, Marcel Berger, Christoph Wyen, Jan Siehl, Jürgen K. Rockstroh, Markus Müller, Gerd Fätkenheuer, (unknown), Maike Nickelsen, Timo Wolf, Ansgar Rieke, Dirk Schürmann, Ralf Schmidmaier, M. Planker, Jürgen Alt, Franz Mosthaf, Andreas Engert, Keikawus Arastéh, Christian Hoffmann	68

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact